Adverse effects of vaccinations and potential therapies against COVID-19

Publication indicates that antiviral therapies are definitely more harmful and less effective as well as less accessible than vaccinations. Antiviral therapies are generally not effective in phase II and III of the disease. The use of antiviral therapies in all patients would doom them to many side effects, and only 10% of patients go from phase I to phase II and require such treatment. The chance of curing COVID-19 patients in phase II and III of the disease is rapidly declining. Vaccinations, on the other hand, are very effective. Confirmed AEFI are rare and intensive research is underway to elucidate their etiopathogenesis. From a biotechnological point of view, vaccination leads to the production of CAR-T-like immunotherapy or monoclonal antibodies, that work from the 1st day of infection, not from the first day of symptom onset, when patients can start some pharmacological therapy. In the case of COVID-19, a clear advantage of vaccination over pharmacological therapy has emerged. Nevertheless, because vaccination may not be effective for all patients, working on therapy should also be intensively carried out. Proper pharmacotherapy administration depends on the quick cooperation of diagnosticians with doctors. It also depends on the development of tests to select therapies and determine in whom a disease such as COVID-19 will change from phase I to phase II. Vaccinated patients will probably respond better to treatments.